C1q Inhibitor Targets Classical Complement Pathway for Autoimmune Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases, such as myasthenia gravis, often rely on non-specific immunosuppressive drugs like steroids, which can have long-term side effects and suppress desirable immune responses, and newer monoclonal antibodies like Eculizumab, which increase susceptibility to infections.
Innovation Solution
Administering compounds that inhibit the classical complement pathway, specifically targeting C1q, C2, or C4 proteins to selectively suppress immune responses and prevent hyperacute graft rejection, using antibodies or synthetic peptide inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific immunosuppressive drugs like steroids are used to treat autoimmune diseases, then immune suppression is achieved, but long-term side effects and suppression of desirable immune responses occur
Solution Approach 1:
The invention segments the immune system into specific pathways (classical complement pathway) and targets only that segment for suppression. By using compounds that specifically inhibit C1q, C2, or C4 proteins, the treatment suppresses only the harmful autoimmune response while leaving other immune functions intact, thereby avoiding the broad immunosuppression and side effects of steroids.
Solution Approach 2:
The invention applies local quality by creating a treatment with selective action on specific complement proteins involved in autoimmune pathology. The compounds inhibit only the classical complement pathway components (C1q, C2, or C4) that are pathogenic in autoimmune diseases, while preserving the functionality of other immune systems and pathways.
2Reliability
If monoclonal antibodies like Eculizumab are used to prevent complement-mediated damage, then protection from autoimmune damage is improved, but susceptibility to infections increases
Solution Approach 1:
The invention segments the complement system into specific components and targets only the upstream elements (C1q, C2, or C4) of the classical pathway. This selective inhibition prevents downstream formation of the membrane attack complex that causes tissue damage, while potentially preserving other protective immune functions better than downstream C5 inhibition.
Solution Approach 2:
The invention applies preliminary action by blocking the classical complement pathway at its initiation stage (C1q, C2, or C4) before the harmful cascade progresses. By preventing early complement activation, the treatment stops the pathological process before it can cause tissue damage, while allowing other immune defense mechanisms to remain functional.
Data Source
AI summary
Disclosed are methods for treating an autoimmune disease or condition in a subject. The methods include administering to the subject a compound which inhibits the subject's classical complement pathway. Also disclosed are methods for suppressing hyperacute graft rejection in a subject. The methods include administering to the subject a compound which inhibits the subject's classical complement pathway. Compositions which include a specific inhibitor of C1q and a pharmaceutically acceptable excipient are also described.